0.50Open0.64Pre Close30 Volume2.26K Open Interest9.00Strike Price1.50KTurnover116.46%IV24.17%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier14DDays to Expiry0.50Extrinsic Value100Contract SizeAmericanOptions Type-0.1388Delta0.0868Gamma56.05Leverage Ratio-0.0201Theta-0.0006Rho-7.78Eff Leverage0.0048Vega
Omeros Stock Discussion
how long will the hold off volume before reaching above 30
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros (OMER) announced successful results from its narsoplimab pivotal trial for treating transplant-associated thrombotic microangiopathy (TA-TMA). The primary statistical analysis showed that patients treated with narsoplimab had an over 3-fold reduction in mortality risk (hazard ratio = 0.32) compared to untreated p...
No comment yet